Mirimostim (macrophage colony-stimulating factor; M-CSF) improves chemotherapy-induced impaired natural killer cell activity, The1 Th2 balance and granulocyte function

Cancer Science

Volumn 94, Issue 9, 2003, Pages 814-820

  Hidaka, Takao ^a   Akada, Shinobu ^b   Teranishi, Akiko ^c   Morikawa, Hajime ^c   Sato, Shinji ^d   Yoshida, Yuji ^d   Yajima, Akira ^d   Yaegashi, Nobuo ^d   Okamura, Kunihiro ^d   Saito, Shigeru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 2; LYMPHOTOXIN; MIRIMOSTIM; PACLITAXEL; SUPEROXIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG SAFETY; FEMALE; GRANULOCYTE; GRANULOCYTE FUNCTION; HELPER CELL; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; MONONUCLEAR CELL; NATURAL KILLER CELL; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADOLESCENT; ADULT; AGED; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OVARIAN NEOPLASMS; SUPEROXIDES; TH1 CELLS; TH2 CELLS;

EID: 10744219822     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01524.x     Document Type: Article

References (39)

1. Hibi S, Yoshihara T, Nakajima F, Misu H, Mabuchi O, Imashuku S. Effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on immune system in pediatric patients with a plastic anemia. Pediatr Hematol Oncol 1994; 11: 319-23.
2. Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997: 15: 3098-105.
3. Rondelli D, Raspadori D, Anasetti C, Bandini G, Re F, Arpinati M, Stanzani M. Morelli A, Baccini C, Zaccaria A, Lemoli RM, Tura S. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells. Bone Marrow Transplant 1998: 22: 631-7.
4. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002; 30: 495-501.
5. Valente JF, Alexander JW, Li BG, Noel JG. Custer DA, Ogle JD, Ogle CK. Effect of in viro infusion of granulocyte colony-stimulating factor on immune function. Shock 2002; 17: 23-9.
6. Mukai M, Bohgaki T, Kondo M, Notoya A, Kohno M. Changes in the T-helper cell 1/T-helper cell 2 balance of peripheral T-helper cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Ann Hematol 2001; 80: 715-21.
7. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514-21.
8. Arpinati M. Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000: 95: 2484-90.
9. Sloand EM, Kim S, Maciejewski JP. Van Rhee F, Chaudhuri A, Barrett J, Young NS. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-74.
10. Durek C, Schafer I, Braasch H, Ulmer AJ, Ernst M, Flad HD. Jocham D, Bohle A. Effects of colony-stimulating factors on cellular cytotoxicity. Cancer Immunol Immunother 1997: 44: 35-40.
11. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG, Bastounis EA, Papamichail M. Granulocyte-macrophage colony-stimulating factor improves immunological paramaters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 1997: 33: 1202-8.
12. Teranishi A, Akada S, Saito S, Hatake K, Morikawa H. Macrophage colony-stimulating factor restored chemotherapy-induced granulocyte dysfanctions role of IL-8 production by monocyte. Int Immunopharmacol 2002; 2: 83-94.
13. Motoyoshi K. Biological activities and clinical application of M-CSF. Int J Hematol 1998; 67: 109-22.
14. Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A, Kobayashi T, Kodera Y, Nishikawa K, Matsuda S, Yamada O, Omoto E, Takeyama H, Tsukuda K, Asou N, Tanimoto M, Shiozaki H, Tomonaga M, Masaoka T. Miura Y, Takaku F, Ohashi Y, Motoyoshi K. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997; 15: 2954-65.
15. Hidaka T, Fujimura M. Nakashima A, Higuma S, Yamagishi N, Tsuda H, Sakai M, Saito S. Macrophage colony-stimulating factor (M-CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte-CSF does not. Jpn J Cancer Res 2002; 93: 426-35.
16. Mizutani K. Takeuchi S, Ohashi Y, Yakushiji M, Nishimura H, Takahashi T, Maruhashi T, Ueda K, Noda K, Watanabe Y, Kawana T, Terashima Y, Ochiai K, Goto S. Takaku F, Motoyoshi K. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: long-term prognosis after five years. Oncol Rep 2003; 10: 127-31.
17. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcR-positive and negative killer cells. J Immunol 1989; 143: 3183-91.
18. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulation of human natural killer cells defined by expression of the leu-7(HNK-1) and Leu(NK15) antigen. J Immunol 1983; 131: 1789-96.
19. Prussin C, Metcalf D. Detection of intracytoplasmic cytokine usihg flow cytometry and direct conjugated anti-cytokine antibodies. Immunol Meth 1995; 188: 117-28.
20. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils A graded response to membrane stimulation. J Immunol 1983; 130: 1910-7.
21. Bass DA, Dechatelet LR, McCall CE. Independent stimulation of motility and the oxidative metabolic burst of human polymorphonuclear leukocytes. J Immunol 1978; 121: 172-8.
22. Hidaka T, Fujimura M, Sakai M, Saito S. Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy. Jpn J Cancer Res 2001; 92: 1251-8.
23. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers J, Owens A, Day R, Ando D, O'Neill C, Buckner D, Singer J. Long-term follow-up of patients with invasive fungal disease who received adjunctive with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422-7
24. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factor: biology and clinical application. N Engl J Med 1989; 321: 1449-59.
25. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM. Granulocyte colony-stimulating factor and neutrophil recovey after high-dose chemotherapy and autologus bone marrow transplantation. Lancet 1989; ii: 891-5.
26. Heil G, Hoelzer D. Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A. A randomized, double-blind, placebo-controlled, phase I study of filgrastim in remission induction and consolidation therapy for adults with de novo myeloid leukemia. Blood 1997; 90: 4710-8.
27. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781-7.
28. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Granulocyte colony-stimulating factor in severe chemotherapy-induced febrile neutropenia. N Engl J Med 1997; 336: 1776-80.
29. Sakurai T, Misawa E, Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony-stimulating factor on cyclophosphamide-injected mouse NK 1.1 + cell activity. Cancer Immunol Immunother. 2000; 49: 94-100
30. Sakurai T, Wakimoto N, Yamada M, Shimamura S, Motoyoshi K. Effects of macrophage colony-stimulating factor on mouse NK 1.1 + cell activity in vivo. Int J Immunopharmacol 1998; 20: 401-13.
31. Misawa E, Sakurai T. Yamada M, Hayasawa H, Motoyoshi K. Effects of macrophage colony-stimulating factor and interleukin-2 administration on NK 1.1 (+) cells in mice. Int J Immunopharmacol 2000; 22: 967-77.
32. Garzetti GG, Ciavattini A, Muzzioli M, Romanini C. Cisplatin-based polychemotherapy reduces natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation. Cancer 1999; 15: 2226-31.
33. Suzuki M, Ohwada M, Shimizu Y, Yamada M, Sato I. An open-label, randomized trial, of the effects of macrophage versus granulocyte colony-stimulating factor on natural killer cell activity, lymphokine activated killer cell activity, interleukin-2 production, and leukocyte count in patients after chemotherapy for ovarian cancer. Curr Ther Res 1997; 58: 698-705.
34. Martinez C, Urbano-Ispizua A, Rozman C, Marin P, Mazzara R, Carreras E, Rovira M, Sierra J, Briones J, Ordinas A, Montserrat E. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996; 72: 269-72.
35. Sica S, Rutella S, Di Mario A, Salutari P, Rumi C, Ortu la Barbera E, Etuk B, Menichella G, D'Onofrio G, Leone G. RhG-CSF in healthy donors: mobilization of peripheral hemopoietic progenitors and effect on peripheral blood leukocytes. J Hemotother 1996; 54: 391-7.
36. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83-243.
37. Tadokoro CE, de Almeida Abrahamsohn I. Bone marrow-derived macrophages grown in GM-CSF or M-CSF differ in their ability to produce IL-12 and to induce IFN-gamma production after stimulation with Trypanosoma cruzi antigens. Immunol Lett 2001; 77: 31-8.
38. Detmers PA, Lo SK, Olsen-Egbert E, Walz A, Baggiolini M, Cohn ZA. Neutrophil-activating protein 1/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990; 171: 1155-62.
39. Hashimoto S, Yoda M, Yamada M, Yanai N, Kawashima T, Motoyoshi K. Macrophage colony-stimulating factor induces interleukin-8 production in human monocytes. Exp Hematol 1996; 24: 123-8.